Seroreactivity to the C6 peptide in Borrelia miyamotoi infections occurring in the northeastern United States
Clinical Infectious Diseases Dec 18, 2017
Molloy PJ, et al. - The authors aimed to assess whether the Food and Drug Administration (FDA)-approved C6 peptide ELISA currently used to diagnose Lyme disease could potentially serve as a diagnostic test for B. miyamotoi infections. This study revealed that C6 ELISA was regularly positive on convalescent phase serum samples of patients from the Northeastern United States with B. miyamotoi infection. However, it was previously found to be a highly specific test for Lyme disease.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries